Trial Profile
Phase I/II trial of BPX-401 in patients with haematological cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs BPX 401 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bellicum Pharmaceuticals
- 12 Mar 2019 According to a Bellicum Pharmaceuticals media release, the company expects to submit an IND application for BPX-603 and to initiate a clinical trial in 2019.
- 07 Nov 2017 According to a Bellicum Pharmaceuticals media release, the company expects to initiate this trial in the fourth quarter of 2017.
- 09 May 2016 According to a Bellicum Pharmaceuticals media release, the company plans to initiate the clinical development of BPX-401 in the second half of 2016.